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Background/aim: Activation-induced cytidine deaminase (AID) enables antibody diversity in B lymphocytes. It may also have an
effect on MDS pathogenesis by causing somatic mutations and by inducing epigenetic changes in myeloid cells. This study aimed to
compare AID expression of MDS patients with healthy controls, of MDS patients in different risk groups, and of MDS patients according
to their treatment.
Materials and methods: Total RNA was isolated and complementary DNA (cDNA) was transcribed from the peripheral blood samples
of MDS patients and healthy controls. AID and the reference gene HPRT1 were analyzed using quantitative real-time PCR (QRT-PCR).
AID expression relative to HPRT1 was calculated. Patients were classified into “lower risk” and “higher risk” subgroups according to
their initial IPSS and IPSS-R scores and their MDS subtypes at the time of study. Patients were also divided into two groups based on
receiving treatment with hypomethylating agents. AID expressions of different groups were compared using the Mann–Whitney U test.
Results: Thirty MDS patients and thirty healthy controls were included. AID expression in MDS patients was significantly higher
compared to healthy controls (p < 0.001). There was no significant difference in AID expression of “lower risk” and “higher risk”
subgroups of patients. Patients that received hypomethylating agents did not have a significant difference in AID expression compared
with patients that did not receive hypomethylating agents.
Conclusion: AID expression is increased in the peripheral blood of MDS patients compared to healthy controls. However, AID
expression is not significantly different in “lower risk” and “higher risk” subgroups and in patients treated with hypomethylating
agents. Increased AID expression may be an early step in MDS pathogenesis.
Key words: Activation induced cytidine deaminase, hypomethylating agents, myelodysplastic syndrome

1. Introduction
Myelodysplastic syndrome (MDS) is a heterogeneous
group of disorders characterized by ineffective and
impaired hematopoiesis in one or more myeloid cell
lineages of bone marrow. It is associated with cytopenias
in the peripheral blood and an increased risk of
transformation to acute myeloid leukemia (AML) [1,2].
Myelodysplastic syndrome can arise de novo (primary) or
secondary
to
ionizing
radiation,
toxin,
or
chemotherapeutic drug exposure [1].
Somatic mutations and epigenetic changes such as
DNA methylation play a role in MDS pathogenesis [3].
Abnormal DNA methylation was detected in the
promoters of tumor suppressor genes in MDS [4]. DNA
methyltransferase (DNMT) 3A mutations were detected
in MDS patients [5]. These mutations were associated
with downregulation of hematopoietic stem cell
differentiation, poor prognosis and rapid progression to
Activation-Induced Cytidine Deaminase (2000).
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AML [6,7]. One of the ten eleven translocation (TET)
family proteins, TET2 catalyzes conversion of 5methylcytosine to 5-hydroxymethylcytosine and its loss
of function mutations are associated with DNA
hypermethylation and gene silencing [8,9]. TET2
mutations were detected in 20%–25% of MDS patients
[10,11]. While some studies associated TET2 mutations
with a better prognosis, their prognostic significance was
unproven in other studies [12,13].
Activation-induced cytidine deaminase (AID), an
enzyme which catalyzes conversion of cytosine to uracil 1,
was originally described as a B lymphocyte specific factor
[14]. AID enables generation of antibody diversity in B
lymphocytes by the mechanisms of somatic
hypermutation, isotype switching, and gene conversion
[15,16]. However, AID may also facilitate tumorigenesis
by inducing proto-oncogene mutations, chromosome
breaks and translocations in other cell lineages [17].
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A study by Rai et al. demonstrated that AID could
catalyze conversion of 5-methylcytosine to thymine by
deamination which could lead to DNA demethylation in
zebrafish [18]. Another study by Popp et al. found
increased DNA methylation in AID deficient primordial
mouse germ cells and hypothesized the possible function
of AID in epigenetic reprogramming [19]. Another study
by Kumar et al. demonstrated AID’s possible role in
deletion of epigenetic memory of pluripotent stem cells,
by its potential function in DNA demethylation. According
to this study, AID seemed to have a fundamental role in
the stabilization and reprogramming of these cells [20].
Thus, we hypothesized that AID expression could have
a role in the pathogenesis of MDS by inducing point
mutations and chromosomal translocations and/or by
interacting with epigenetic mechanisms of DNA
methylation and demethylation. The aim of this study is to
compare AID mRNA expression levels of MDS patients
with healthy controls, AID expression levels of MDS
patients in different risk groups and AID expression levels
of patients that received hypomethylating agents with
those that did not receive this treatment.
2. Materials and methods
2.1. MDS patients and healthy control group
We enrolled 30 MDS patients who visited the outpatient
clinic or who were admitted to the inpatient ward of
Istanbul University, Istanbul Faculty of Medicine, Division
of Hematology between December 2016 and March 2017
in this study. We took their blood samples. We also
obtained blood samples of an age-matched healthy
control group of thirty people. All participants in both the
patient group and healthy control group provided
informed consent in the format required by the
institutional research committee.
We recorded the history, physical examination
findings, complete blood count, bone marrow biopsy, and
cytogenetic findings of MDS patients at the time of
diagnosis. We analyzed MDS subtypes both at the time of
diagnosis and at the time of sample collection because
transformation to other subtypes occurred in some
patients. We determined MDS subtypes according to the
2008 classification of World Health Organization (WHO)
[21]. We also recorded the International Prognostic
Scoring System (IPSS) and the Revised International
Prognostic Scoring System (IPSS-R) scores of the patients
at the time of diagnosis [22,23]. We then determined the
patients that were treated with hypomethylating agents
(azacitidine and decitabine). Next, we classified the
patients into “lower risk” and “higher risk” subgroups
according to the IPSS and IPSS-R scores at the time of
diagnosis. Patients in “low” and “intermediate-1”
categories according to IPSS were classified as “lower
risk” and patients in “intermediate-2” and “high”
categories according to IPSS were classified as “higher
risk”. Patients in “very low”, “low”, and “intermediate”
categories according to IPSS-R were classified as “lower
risk,” and patients in “high” and “very high” categories
2452

according to IPSS-R were classified as “higher risk”.
Afterward, we made another risk stratification according
to MDS subtype at the time of sample collection. Patients
that had refractory anemia with excess blasts-1 (RAEB-1)
and refractory anemia with excess blasts-2 (RAEB-2)
were classified as “higher risk” and all other MDS subtypes
were classified as “lower risk”.
Our study protocol received the approval of the
institutional research committee. All procedures that we
performed in this study were in accordance with the
ethical standards of the institutional research committee
and with 1964 Helsinki declaration and its later
amendments.
2.2. Determination of AID mRNA expression levels in
peripheral blood samples
We collected the peripheral blood samples from patients
and healthy controls in sterile tubes containing
etylenediaminetetraacetic acid (EDTA). We isolated total
RNA using High Pure RNA Isolation Kit (Roche), in
accordance with the instructions of the manufacturer. We
measured the density of RNAs that were obtained from
the samples spectrophotometrically using NanoDrop
2000c (Thermo Scientific, USA). We transcribed
complementary DNA (cDNA) from 100 ng of total RNA
using Fermentas, RevertAid First Strand cDNA Synthesis
Kit (Roche). We performed TaqMan-based quantitative
real-time PCR (QRT-PCR) using a LightCycler®TaqMan
Master Kit (Roche Diagnostics) and we used a
LightCycler® 480II instrument (Roche Diagnostics,
Mannheim, Germany) to analyze the target gene AID and
the reference gene HPRT1 (hypoxanthine phosphoribosyl
transferease-1). Primers and probes were designed at the
Universal Probe Library website of Roche. Primers
specific to the target gene AID were as follows: forward:
5′-TGGACACCACTATGGACAGC-3’ and reverse: 5’GCGGACATTTTTGAATTGGT-3’. Primers specific to the
reference gene HPRT1 were as follows: forward: 5’GACCAGTCAACAGGGGACAT-3’
and
reverse:
5′GTGTCAATTATATCTTCCACAATCAAG-3′.
To calculate the relative expression, we obtained
CT values of AID and HPRT for all samples. We obtained
the normalized expression for each sample by subtracting
the CT of HPRT1 from the CT of AID of the same sample.
This was designated as ΔCT. Afterward, we transformed
this value using 2−(ΔCT) formula [24].
2.3. Statistical analysis
Firstly, we reported AID mRNA expression levels of MDS
patients and healthy controls using mean and standard
deviation. Next, we checked these expression levels for
normal distribution. Due to their nonnormal distribution,
we then reported AID mRNA expression levels of MDS
patients and healthy controls using median, first, and
third quartile values. Next, we used the nonparametric
Mann–Whitney U test to compare AID mRNA expression
levels in both groups. We then checked AID mRNA
expression levels of “lower risk” and “higher risk” MDS
subgroups according to IPSS and IPSS-R scores at the time
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of diagnosis and according to MDS subtypes at the time of
sample collection for normal distribution. None of the
subgroups demonstrated a normal distribution. We then
reported AID mRNA expression levels of “lower risk” and
“higher risk” subgroups using median, first, and third
quartile values. Next, we used the nonparametric Mann–
Whitney U test to compare AID mRNA expression levels in
“lower risk” and “higher risk” subgroups. After that, we
checked AID mRNA expression levels of patients that
received hypomethylating agents and those that did not
receive hypomethylating agents for normal distribution.
Due to absence of normal distribution, we reported AID
mRNA expression levels of “hypomethylating agent” and
“no hypomethylating agent” subgroups using median,
first, and third quartile values. After that, we used
nonparametric Mann–Whitney U test to compare AID
mRNA expression levels in these two subgroups. Finally,
we separately compared the AID expressions of
“hypomethylating
agent”
subgroup
and
“no
hypomethylating agent” subgroup with the healthy
control group.
Hypotheses were two tailed with p < 0.05 accepted as
the cutoff for statistical significance. We performed all
statistical analyses using SPSS 17.0.
3. Results
3.1. General characteristics of patients and healthy
controls
We enrolled thirty patients and thirty healthy controls
in our study. In the patient group, there were 15 male and
15 female patients. Mean age of the patients was 63.03 ±
9.67. In the healthy control group, there were 15 males
and 15 females. Mean age of the healthy control group was
59.10 ± 9.39. Characteristics of patients and healthy
controls are demonstrated in Tables 1 and 2, respectively.
Conventional cytogenetic analysis was performed in 27
patients (90%), cytogenetic analysis was not performed in
3 patients (10%) because a sufficient number of
metaphases was not obtained. Twenty-two patients
(73.33%) had normal karyotype. 1 patient (3.33%) had a
karyotype of 46, XX, del(5q), 1 patient (3.33%) had a
karyotype of 46, XX, del(20q), 1 patient had a karyotype of
45, X-Y (3.33%), 1 patient had a karyotype of 45, XX, 7,der(14) (3.33%), 1 patient had a karyotype of 46, XY,
der(1),der(2),der(20) (3.33%).
We classified thirty MDS patients into subtypes
according to 2008 classification of World Health
Organization. Their MDS subtypes at the time of diagnosis:
9 patients (30%) had RCUD (refractory cytopenia of
unilineage dysplasia), 1 patient (3.33%) had RARS
(refractory anemia with ring sideroblasts), 8 patients
(26.67%) had RCMD (refractory cytopenia of multilineage
dysplasia), 1 patient (3.33%) had MDS with 5q deletion, 4
patients (13.33%) had RAEB-1 (refractory anemia with
excess blasts-1), and 7 patients (23.33%) had RAEB-2
(refractory anemia with excess blasts-2). MDS subtypes of
patients at the time of sample collection: 7 patients
(23.33%) had RCUD, 5 patients (16.67%) had RCMD, 1

patient (3.33%) had MDS with 5 q deletion, 7 patients
(23.33%) had RAEB-1, and 10 patients (33.33%) had
RAEB-2.
Nineteen
(63.33%)
MDS
patients
received
hypomethylating agents as treatment. Eighteen (60%) of
these patients received azacitidine, 5 (16.67%) of them
received decitabine. Four of these patients received both
treatments. The remaining 11 patients received only
supportive treatment such as erythropoietin and
transfusions.
We classified IPSS and IPSS-R scores at the time of
diagnosis for 27 patients, in 3 patients, these scores were
not calculated due to the lack of cytogenetic analysis.
Mean IPSS was 0.72 ± 0.79, with a minimum score of 0 and
a maximum score of 3. Twenty-two patients were in the
“lower risk” subgroup and 5 patients were in the “higher
risk” subgroup. Mean IPSS-R was 3.57 ± 1.88 with a
minimum score of 1 and a maximum score of 8.5. Nineteen
patients were in the “lower risk” subgroup and 8 patients
were in the “higher risk” subgroup. Next, we classified the
patients into “higher risk” and “lower risk” subgroups
according to their MDS subtypes at the time of sample
collection. Thirteen patients were in the “lower risk”
subgroup and 17 patients were in the “higher risk”
subgroup.
3.2. Comparison of AID expression in MDS patients
and healthy controls
Mean AID mRNA level in the peripheral blood of the 30
MDS patients was 0.034410 ± 0.026487 and the mean AID
mRNA level of 30 healthy controls was 0.006060 ±
0.003260 (Figure 1). The distribution of AID expression of
both MDS patients and healthy controls was nonnormal.
Since both groups demonstrated a nonnormal
distribution, we compared AID expression of MDS
patients and healthy controls using the nonparametric
Mann–Whitney U test. AID mRNA levels in MDS patients
(median: 0.021906; Q1: 0.015775–Q3: 0.057967) was
higher compared to healthy controls (median: 0.004792;
Q1:0.003569–Q3: 0.009088). The Mann–Whitney U test
indicated that this difference was statistically significant
(U = 47, p < 0.001).
3.3. Comparison of AID expression in “lower risk” and
“higher risk” subgroups according to IPSS, IPSS-R and
MDS subtypes
According to IPSS, the mean AID mRNA level was
0.039728 ± 0.028614 in the “lower risk” subgroup, and
was 0.022977 ± 0.010285 in the “higher risk” subgroup
(Figure 2). Neither the “lower risk” subgroup nor the
“higher risk” subgroup demonstrated a normal
distribution. Therefore, we used the nonparametric
Mann–Whitney U test to compare these subgroups. AID
mRNA expression in the “lower risk” subgroup (median:
0.027776; Q1: 0.016477–Q3: 0.067757) and the “higher
risk” subgroup (median: 0.017579; Q1: 0.014563–Q3:
0.034091) were compared and the Mann–Whitney U test
indicated that this difference was not statistically
significant. (U = 39.5, p = 0.333).
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Table 1. Clinical characteristics of the myelodysplastic syndrome patients.
IPSS score at the
MDS subtype at
Age and
Cytogenetic analysis at the
time of
the time of
Patient
sex
time of diagnosis
diagnosis
diagnosis
(risk group)
58,
1
RCUD
46, XX
0 (lower)
female
73,
2
RAEB-2
46, XX
1 (lower)
female

MDS subtype
at the time of
study

Treatment
received

2 (lower)

RAEB-2

Azacitidine

3.5 (lower)

RAEB-2

Azacitidine

2 (higher)

5.5 (higher)

RAEB-2

Azacitidine and
decitabine

1 (lower)

3.5 (lower)

RAEB-1

Azacitidine

3

69, male RAEB-2

4

57, male RCMD

5

42, male RAEB-1

46, XY, der(1), der(2),
der(20)
46, XY

1 (lower)

5.5 (higher)

RAEB-1

Azacitidine

6

72, male RAEB-2
78,
RCMD
female
69, male RAEB-2

46,XX/47,XX+8,der21
(p11),del(20q)
46, XY

-

-

RAEB-2

Azacitidine

1.5 (higher)

4 (lower)

RCMD

Supportive

2 (higher)

5 (higher)

RAEB-2

Azacitidine

-

-

-

RAEB-1

46, XX

1 (lower)

5.5 (higher)

RAEB-1

11

56, male RAEB-1
73,
RAEB-1
female
61, male RCUD

-

-

-

RCUD

Decitabine
Azacitidine and
decitabine
Supportive

12

62, male RCMD

46, XY

0.5 (lower)

4 (lower)

RCMD

13

58, male RAEB-1

45X,-Y

0.5 (lower)

3.5 (lower)

RAEB-1

14

63, male RCMD

0.5 (lower)

2.5 (lower)

RCMD

15

85, male RCUD

46, XY
46, XY/46, XY, t(5;21)
(q33;q22)

Supportive
Azacitidine and
decitabine
Supportive

0.5 (lower)

2.5 (lower)

RCUD

Supportive

5q deletion

46, XX, del(5q)

0.5 (lower)

2.5 (lower)

5q deletion

Supportive

RARS

46, XX

0 (lower)

2.5 (lower)

RAEB-1

Azacitidine

RCMD

46, XY

0 (lower)

2.5 (lower)

RAEB-1

Azacitidine

RCMD

46, XX

0 (lower)

1.5 (lower)

RCMD

Azacitidine

RCMD

46, XX, del(20q)

0 (lower)

1.5 (lower)

RCMD

Supportive

RAEB-2

45, XX,-7 der(14)

3 (higher)

8.5 (higher)

RAEB-2

Supportive

46, XY

1 (lower)

5.5 (higher)

RAEB-2

Azacitidine and
decitabine

RCMD

46, XX

0.5 (lower)

2.5 (lower)

RAEB-2

Azacitidine

RCUD

46, XX

0 (lower)

1 (lower)

RCUD

Supportive

RCUD

46, XX

0 (lower)

2 (lower)

RCUD

Azacitidine

RCUD

46, XX

0 (lower)

1 (lower)

RCUD

Azacitidine

RCUD

46, XX

0.5 (lower)

2 (lower)

RCUD

Supportive

RCUD

46, XX, del(20q)

0 (lower)

6.5 (higher)

RAEB-2

Azacitidine

RCUD

46, XY

0 (lower)

4 (lower)

RCUD

Supportive

46, XY

2 (higher)

6 (higher)

RAEB-2

Azacitidine

7
8
9
10

16
17
18
19
20
21
22

62,
female
57,
female
63, male
53,
female
78,
female
39,
female

79, male RAEB-2

29

70,
female
71,
female
69,
female
64,
female
70,
female
69,
female
44, male

30

73, male RAEB-2

23
24
25
26
27
28

46, XY

IPSS-R score at
the time of
diagnosis
(risk group)

Abbreviations: RAEB-1: Refractory anemia with excess blasts-1, RAEB-2: Refractory anemia with excess blasts-2, RARS:
Refractory anemia with ring sideroblasts, RCMD: Refractory cytopenia of multilineage dysplasia, RCUD: Refractory
cytopenia of unilineage dysplasia
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According to IPSS-R, mean AID mRNA level was
0.040604 ± 0.028518 in the “lower risk” subgroup, and
was 0.027178 ± 0.021065 in the “higher risk” subgroup
(Figure 3). Neither the “lower risk” subgroup nor the
“higher risk” subgroup demonstrated a normal
distribution. Therefore, we used the nonparametric
Mann–Whitney U test to compare these subgroups. AID
mRNA expression in the “lower risk” subgroup (median:
0.030606; Q1: 0.016688–Q3: 0.066985) and the “higher
risk” subgroup (median: 0.017162; Q1: 0.015570–Q3:
0.034736) were compared and the Mann–Whitney U test
indicated that this difference was not statistically
significant. (U = 56; p = 0.288).
According to MDS subtypes of the patients at the time
of sample collection, mean AID mRNA level was 0.043139
± 0.030846 in the “lower risk” subgroup and 0.027735 ±
Table 2. Characteristics of the healthy controls.
Healthy control

Age and sex

1

55, male

2

57, female

3

57, female

4

71, female

5

55, female

6

54, female

7

47, female

8

56, female

9

56, female

10

76, female

11

49, female

12

47, male

13

67, male

14

68, female

15

46, female

16

45, female

17

62, male

18

62, male

19

43, male

20

65, male

21

62, male

22

66, female

23

47, male

24

67, male

25

59, male

26

72, male

27

70, male

28

75, male

29

41, female

30

57, male

Figure 1. AID mRNA expression levels of MDS patients and
healthy controls.

Figure 2. AID mRNA expression levels of “lower risk” and
“higher risk” MDS patients according to their initial IPSS
score.
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Figure 3. AID mRNA expression levels of “lower risk” and
“higher risk” MDS patients according to their initial IPSS-R
score.

Figure 4. AID mRNA expression levels of “lower risk” and
“higher risk” MDS patients according to their MDS subtype at
the time of the study.
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0.021183 in the “higher risk” subgroup (Figure 4). Neither
the “lower risk” subgroup nor the “higher risk” subgroup
demonstrated a normal distribution. Therefore, we
used the nonparametric Mann–Whitney U test to compare
these subgroups. AID mRNA expression in the “lower risk”
subgroup (median: 0.030606; Q1: 0.016265–Q3:
0.069514) and the “higher risk” subgroup (median:
0.019915; Q1:0.015570–Q3:0.034091) were compared,
and the Mann–Whitney U test indicated that this
difference was not statistically significant (U = 81; p =
0.217).
3.4. Comparison of AID expression in patients that
received hypomethylating agents and patients that
did not receive hypomethylating agents
Mean AID mRNA level of the patients that received
hypomethylating agents (azacitidine and/or decitabine)
was 0.032146 ± 0.027421. Mean AID mRNA level of
patients that did not receive hypomethylating agents was
0.038319 ± 0.025584 (Figure 5). Neither group
demonstrated a normal distribution; therefore, we used
the nonparametric Mann–Whitney U test to compare
them. AID mRNA expression in the “hypomethylating
agent” group (median: 0.020263; Q1: 0.015570–Q3:
0.035380) and the “no hypomethylating agent” (median:
0.022020; Q1: 0.015843–Q3: 0.066985) group were
compared and the Mann–Whitney U test indicated that
this difference was not statistically significant (U = 90; p =
0.533).

Figure 5. AID mRNA expression levels of patients that
received and that did not receive hypomethylating agents.
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When we compared AID expression of each of these
subgroups separately with the healthy control group, we
found that both subgroups had a significantly higher AID
expression (U = 44; p < 0.001 for patients that received
hypomethylating agents and U = 3; p < 0.001 for patients
that did not receive hypomethylating agents) compared to
the healthy control group.
4. Discussion
Increased AID mRNA expression may have a role in the
pathogenesis of MDS, a premalignant disease with an
increased risk of leukemic transformation, by inducing
mutations and cytogenetic abnormalities.
AID is known to cause DNA mutations and double
strand breaks. This enables antibody diversity in B
lymphocytes, but in other cell lines it can lead to tumor
formation by inducing chromosome translocations and
protooncogene mutations [17].
In a study by Marusawa et al., constitutive and
excessive expression of AID in transgenic mice was
demonstrated to cause lymphoma by inducing mutations
in T cell receptors and in genes such as myc. In the same
study, there was also an increase in dysgenetic lesions in
lungs and in epithelial neoplasia of liver and stomach [25].
AID expression was present in gastric tissue infected with
Helicobacter pylori, and a relationship between epithelial
neoplasia and increased AID expression was proposed
[26]. AID expression was associated with many different
types of hematological malignancies such as Burkitt
leukemia/lymphoma, diffuse large B cell lymphoma,
Philadelphia chromosome positive acute lymphoblastic
leukemia, chronic lymphocytic leukemia, and chronic
myeloid leukemia in blastic crisis [27–32].
AID mRNA expression can also play a role in MDS
pathogenesis through its possible role in the epigenetic
mechanisms of DNA methylation and demethylation.
Mutations in genes which regulate DNA methylation,
such as DNMT and TET 2, were demonstrated in MDS
patients [10,11,33,34]. An animal study by Arioka et al.
suggested the possible role of AID in regulating
intracellular localization of TET proteins. This study also
proposed the possible significance of the coordinated
function of AID and TET in regulating epigenetic changes
[35]. In another study by Tsai et al., a possible role of AID
in stabilization of DNMT was hypothesized [36].
According to these studies, AID may have a functional
interaction with TET and DNMT, two genes whose roles in

epigenetic changes in MDS pathogenesis have already
been demonstrated.
DNMT1 and DNMT3A are upregulated and
overexpressed in MDS patients, causing increased
methylation of cytosine residues [37]. TET2, whose loss of
function mutations are demonstrated in MDS, enables
demethylation by catalyzing conversion of 5methylcytosine to 5-hydroxymethylcytosine [8,9]. AID
contributes to DNA demethylation by catalyzing
deamination of 5-hydroxymethylcytosine to 5hydroxymethyluracil. This activates base excision repair
mechanisms that convert 5-hydroxymethyluracil to
unmethylated cytosine [38]. According to the study by
Morgan et al., AID may play an additional role in DNA
demethylation by also deaminating 5- methylcytosine to
5-methyluracil (thymine) [39].
Figure 6 demonstrates the role of DNMT and TET in
DNA methylation-demethylation reactions and the
possible role of AID in these reactions [38].
In MDS patients, AID mRNA expression may be
increased in order to compensate the increased DNA
methylation (due to mutations causing DNMT
overexpression) and decreased DNA demethylation (due
to TET-2 mutations causing loss of function). Due to
overexpression of DNMT, 5-methylcytosine production is
increased. Since TET2 function is lost, 5-methylcytosine
cannot be converted to 5-hydroxymethylcytosine. AID
expression may increase as a compensating mechanism,
enabling DNA demethylation by converting increased 5methylcytosine is to 5-methyluracil (thymine). Therefore,
increased AID expression can be secondary to mutations
in DNMT and/or TET2 rather than a primary factor in the
disease pathogenesis.
However, not all studies support this hypothesis. The
review of DNA demethylation pathways by Bochtler et al.
demonstrated that recent studies investigating the
expression of AID on embryonic stem cells and the
involvement of AID in DNA demethylation in these cells
have yielded conflicting results. Some studies supported
AID’s role, whereas some studies argued that it does not
play a role in DNA demethylation [40]. In this review, the
authors also stated that according to some studies, AID’s
catalytic effect on 5-methylcytosine as a substrate was
much less efficient than its effect on cytosine, which
undermined the direct role of AID on DNA demethylation
[40]. The authors then proposed that AID acted indirectly
on DNA demethylation by acting on cytosine, triggering

Figure 6. Role of DNMT, TET, and AID in DNA methylation-demethylation reactions. AID: Activation induced cytidine deaminase,
DNMT1: DNA methyltransferase 1, TET2: Ten-eleven translocation family protein 2.
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Figure 7. Increased AID expression may occur in the earlier steps of MDS pathogenesis. AID: Activation induced cytidine deaminase,
MDS: Myelodysplastic syndrome.

repair mechanisms which also replaced the 5methylcytosine molecules in the vicinity [40].
Although the AID expression is significantly increased
in MDS patients compared to healthy controls, there was
no statistically significant difference in AID mRNA levels
of “lower risk” and “higher risk” subgroups according to
IPSS, IPSS-R, and MDS subtypes. Considering our findings,
we hypothesize that increased AID mRNA expression may
occur in the earlier steps of MDS pathogenesis. As normal
myeloid cells transform into “lower risk” MDS clones, AID
expression increases. This increase may account for the
statistically significant increase in AID expression of MDS
patients compared to healthy controls. However, as
“lower risk” MDS clones transform to “higher risk” clones,
there is no further increase in AID expression because this
change has already occurred in earlier steps. This
hypothesis is summarized in Figure 7.
The low number of patients is a limitation of our study.
There are 4 risk groups in the original IPSS classification
and 5 risk groups in the original IPSS-R classification.
However, due to the low number of our patients, they
were classified into “lower risk” and “higher risk”
subgroups according to these scoring systems and then a
comparison of AID expression of these subgroups was
performed. Further studies which include more patients
will enable AID expression of each risk group to be
directly compared with each other. Due to the low number
of patients in our study, instead of comparing AID
expression of each MDS subtype with each other, we
divided the MDS subtypes into 2 categories and compared
the AID expression of these 2 categories. Due to the
heterogeneous nature of MDS, AID expression of MDS
subtypes could differ from each other. Therefore, larger
studies that compare AID expression in each different
MDS subtype are also necessary.
Our study compared the AID expression of patients
that received hypomethylating agents with those that did
not receive this treatment. Although both subgroups had
a significantly higher AID expression compared to healthy
controls, there was no significant difference in the AID
expression of these 2 subgroups. Due to the crosssectional nature of our study, we were unable to compare
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